Goldman Sachs’s Clovis Oncology, Inc. CLVS Stock Holding History

Goldman Sachs’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-36,900	Closed	-$385K	–	5654
2019 Q4	$385K	Sell	36,900 -1,000	-3%	-$7.27K	﹤0.01%	4641
2019 Q3	$149K	Sell	37,900 -14,600	-28%	-$118K	﹤0.01%	4902
2019 Q2	$781K	Sell	52,500 -89,000	-63%	-$1.61M	﹤0.01%	4147
2019 Q1	$3.51M	Buy	141,500 +101,500	+254%	+$2.54M	﹤0.01%	3238
2018 Q4	$718K	Buy	+40,000	New	+$817K	﹤0.01%	4161
2018 Q1	–	Sell	-76,300	Closed	-$5.19M	–	6504
2017 Q4	$5.19M	Buy	76,300 +18,300	+32%	+$1.28M	﹤0.01%	2985
2017 Q3	$4.78M	Sell	58,000 -37,500	-39%	-$2.97M	﹤0.01%	3189
2017 Q2	$8.94M	Buy	+95,500	New	+$5.84M	﹤0.01%	2590
2017 Q1	–	Sell	-55,000	Closed	-$2.44M	–	7078
2016 Q4	$2.44M	Sell	55,000 -100,000	-65%	-$3.52M	﹤0.01%	3671
2016 Q3	$5.59M	Buy	155,000 +40,400	+35%	+$867K	﹤0.01%	2945
2016 Q2	$1.57M	Hold	114,600	–	–	﹤0.01%	3818
2016 Q1	$2.2M	Sell	114,600 -17,800	-13%	-$377K	﹤0.01%	3385
2015 Q4	$4.63M	Buy	+132,400	New	+$8.54M	﹤0.01%	2899
2015 Q2	–	Sell	-50,000	Closed	-$3.71M	–	7498
2015 Q1	$3.71M	Buy	+50,000	New	+$3.53M	﹤0.01%	3183
2014 Q2	–	Sell	-2,500	Closed	-$173K	–	7189
2014 Q1	$173K	Sell	2,500 -37,100	-94%	-$2.72M	﹤0.01%	6167
2013 Q4	$2.39M	Buy	39,600 +30,600	+340%	+$1.66M	﹤0.01%	3892
2013 Q3	$547K	Buy	+9,000	New	+$638K	﹤0.01%	5103

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Goldman Sachs's CLVS Position: Q4 2022 in Review

Goldman Sachs sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 139,904 shares — an estimated $166K sold.

Goldman Sachs first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $65.4M in Q4 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Goldman Sachs reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 139,904 Clovis Oncology, Inc. shares in Q4 2022, an estimated $166K.
Goldman Sachs first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
Goldman Sachs's Clovis Oncology, Inc. position peaked at $65.4M in Q4 2015.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.